Safety of Tyrosine Kinase Inhibitors in Patients With Differentiated Thyroid Cancer: Real-World Use of Lenvatinib and Sorafenib in Korea

Background: Thyroid cancer has become the most common cancer in Korea. Generally, thyroid cancer patients have a good prognosis; however, 15–20% of patients experience recurrence or distant metastasis or are refractory to standard treatment. We assessed the safety of sorafenib and lenvatinib in pati...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Front Endocrinol (Lausanne)
Prif Awduron: Kim, Soo Young, Kim, Seok-Mo, Chang, Hojin, Kim, Bup-Woo, Lee, Yong Sang, Chang, Hang-Seok, Park, Cheong Soo
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Frontiers Media S.A. 2019
Pynciau:
Endocrinology
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6581694/
https://ncbi.nlm.nih.gov/pubmed/31244783
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fendo.2019.00384
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg